Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2. Overexpression of miR302-367 cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

Published byEmery McDaniel Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2. Overexpression of miR302-367 cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression."— Presentation transcript:

1 Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. (A) At E18.5, Nkx2.5cre:R26R-miR Tg/+ mutants have an enlarged heart with thickened ventricular myocardium and ventricular septal defects compared to Nkx2.5cre controls. (B) Cardiomegaly and increased cardiomyocyte proliferation in Nkx2.5cre:R26R-miR Tg/+ mutant hearts at P20. (A and B) Immunostainings for PH3 and α-actinin and wheat germ agglutinin (WGA) show the number of mitotic cardiomyocytes. Scale bars, 100 μm. High-magnification reveals PH3+ cardiomyocytes. LA, left atrium. Data are means ± SEM (n = 3). P values determined by Student’s t test. Ying Tian et al., Sci Transl Med 2015;7:279ra38 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 2. Overexpression of miR302-367 cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression."

Similar presentations

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Human Ventricular Unloading Induces Cardiomyocyte.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Human Ventricular Unloading Induces Cardiomyocyte.
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.
Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.
Soft robotic device applied to the left side in a coronary ligation HF model. Soft robotic device applied to the left side in a coronary ligation HF model.

Soft robotic device applied to the left side in a coronary ligation HF model. Soft robotic device applied to the left side in a coronary ligation HF model.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 1. Bj mutant exhibits outflow tract malalignment defects.

Fig. 1. Bj mutant exhibits outflow tract malalignment defects.
Fig. 8. The cohort of 3KO/CCS-LacZ embryos that survived to later timepoints showed marked hyperplasia of the ventricular conduction system (A–F).(B) Severe.

Fig. 8. The cohort of 3KO/CCS-LacZ embryos that survived to later timepoints showed marked hyperplasia of the ventricular conduction system (A–F).(B) Severe.
Fig. 1 Characterization of decellularized zECM.

Fig. 1 Characterization of decellularized zECM.
Fig. 2. Spontaneous inflammasome activation by pyrin S242R.

Fig. 2. Spontaneous inflammasome activation by pyrin S242R.
Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.
Fig. 1. Generation of the ΔEx50 mouse model.

Fig. 1. Generation of the ΔEx50 mouse model.
Fig. 1 ZIKV RNA in blood and tissues.

Fig. 1 ZIKV RNA in blood and tissues.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 3 The electrical contact of direct-printed and reconfigured liquid metals. The electrical contact of direct-printed and reconfigured liquid metals.

Fig. 3 The electrical contact of direct-printed and reconfigured liquid metals. The electrical contact of direct-printed and reconfigured liquid metals.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.

Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Similar presentations

Ads by Google